The retraction of three papers on treating COVID-19 with hydroxychloroquine reflect a crisis in the scientific community: how to handle data from private companies. What reforms are necessary to avoid such data-based scandals in the future?
Those in rural areas face a significantly higher risk of death from common causes than their urban counterparts. Is telemedicine the solution to this disparity?
Romoser's claims concerning the existence of life on Mars raise questions about the requirements for having justified beliefs.
Is healthcare like any other consumer good in the marketplace or does it occupy a privileged position that requires special protections? Our answer has far-reaching implications.
Given the profound societal effect that scientific studies can have, are there kinds of research that shouldn't be done or results that shouldn't be published? Can scientific censorship be justified?
Egg donation holds invaluable promise for many, but it is also rife with societal implications for all.
The recent passing of Belgian Paralympian Marieke Vervoort prompts reflection on the thorny issues surrounding aid in dying legislation.
NDs and MDs are both concerned for the public's health and patient autonomy, but is formally distinguishing NDs from unlicensed practitioners an advancement of, or a hindrance to, those goals?
Sensationalism of budding science and developing technology is only becoming more exaggerated. And CRISPR is no exception.
A recent case highlights the conflict between paternalism and autonomy in the medical field. In what sense might one's decision to pursue an experimental treatment not be one's own?